Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens

Cancer

Volumn 121, Issue 20, 2015, Pages 3612-3621

  Thompson, Philip A ^a   O'Brien, Susan M ^b   Wierda, William G ^a   Ferrajoli, Alessandra ^a   Stingo, Francesco ^a   Smith, Susan C ^a   Burger, Jan A ^a   Estrov, Zeev ^a   Jain, Nitin ^a   Kantarjian, Hagop M ^a   Keating, Michael J ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

chronic lymphocytic leukemia (CLL); complex karyotype; del(17p); ibrutinib; relapsed and refractory

Indexed keywords

BENDAMUSTINE; BETA 2 MICROGLOBULIN; FLUDARABINE; IBRUTINIB; RITUXIMAB; ANTINEOPLASTIC AGENT; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RESISTANCE; CHROMOSOME 17P; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHROMOSOME DELETION 17P; CHRONIC LYMPHATIC LEUKEMIA; DIARRHEA; DRUG RESPONSE; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; KARYOTYPING; LEUKEMIA REMISSION; LYMPHOCYTOSIS; MAJOR CLINICAL STUDY; MALE; METAPHASE; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENT INFECTION; VON WILLEBRAND DISEASE; CHROMOSOME 17; GENETICS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; PATHOLOGY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY;

ABNORMAL KARYOTYPE; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 17; CYTOGENETIC ANALYSIS; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PYRAZOLES; PYRIMIDINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84943579968     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29566     Document Type: Article

References (25)

1. Hallek M, Fischer K, Fingerle-Rowson G, et al., Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010; 376: 1164-1174.
2. Dreger P, Dohner H, Ritgen M, et al., Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood. 2010; 116: 2438-2447.
3. Schetelig J, van Biezen A, Brand R, et al., Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. J Clin Oncol. 2008; 26: 5094-5100.
4. Byrd JC, Furman RR, Coutre SE, et al., Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013; 369: 32-42.
5. O'Brien SM, Coutre SE, Flinn I, et al., Independent evaluation of ibrutinib efficacy 3 years post-initiation of monotherapy in patients with chronic lymphocytic leukemia/small lymphocytic leukemia including deletion 17p disease [abstract 7014]. J Clin Oncol. 2014 32 (suppl): 5s.
6. Woyach JA, Furman RR, Liu TM, et al., Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014; 370: 2286-2294.
7. Jain P, Keating M, Wierda W, et al., Outcomes of patients with chronic lymphocytic leukemia (CLL) after discontinuing ibrutinib. Blood. 2015; 125: 2062-2067.
8. Haferlach C, Dicker F, Schnittger S, Kern W, Haferlach T,. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. Leukemia. 2007; 21: 2442-2451.
9. Juliusson G, Robert KH, Ost A, et al., Prognostic information from cytogenetic analysis in chronic B-lymphocytic leukemia and leukemic immunocytoma. Blood. 1985; 65: 134-141.
10. Juliusson G, Oscier DG, Fitchett M, et al., Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med. 1990; 323: 720-724.
11. Woyach JA, Lozanski G, Ruppert AS, et al., Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features. Leukemia. 2012; 26: 1442-1444.
12. Jaglowski SM, Ruppert AS, Heerema NA, et al., Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia. Br J Haematol. 2012; 159: 82-87.
13. Oscier DG, Gardiner AC, Mould SJ, et al., Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood. 2002; 100: 1177-1184.
14. Bentz M, Huck K, du Manoir S, et al., Comparative genomic hybridization in chronic B-cell leukemias shows a high incidence of chromosomal gains and losses. Blood. 1995; 85: 3610-3618.
15. Dicker F, Schnittger S, Haferlach T, Kern W, Schoch C,. Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: a study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood. 2006; 108: 3152-3160.
16. Burger JA, Keating MJ, Wierda WG, et al., Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. The Lancet Oncology. 2014; 15: 1090-1099.
17. Brown JR, Barrientos JC, Barr PM, et al., Ibrutinib in combination with bendamustine and rituximab is active and tolerable in patients with relapsed/refractory CLL/SLL: final results of a phase 1b study. Paper presented at: 55th ASH Annual Meeting and Exposition; December 7-10, 2013; New Orleans, LA.
18. Castoldi GL, Lanza F, Cuneo A,. Cytogenetic aspects of B-cell chronic lymphocytic leukemia: their correlation with clinical stage and different polyclonal mitogens. Cancer Genet Cytogenet. 1987; 26: 75-84.
19. Shaffer LGS, Marilyn L,. Campbell, Lynda J, eds. ISCN 2009: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger; 2009.
20. Kaplan EL, Meier P,. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
21. Peto R, Pike MC, Armitage P, et al., Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer. 1977; 35: 1-39.
22. Cox DR, Snell EJ,. Analysis of Binary Data. 2nd ed. London, United Kingdom: Chapman & Hall; 1989.
23. Muthusamy N, Breidenbach H, Andritsos L, et al., Enhanced detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide in combination with pokeweed mitogen and phorbol myristate acetate. Cancer Genet. 2011; 204: 77-83.
24. Khouri IF, Bassett R, Poindexter N, et al., Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome. Cancer. 2011; 117: 4679-4688.
25. Sorror ML, Storer BE, Sandmaier BM, et al., Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol. 2008; 26: 4912-4920.